|
Through
a series of acquisitions, Albea Pharmaceuticals intends
to build a rapidly growing, profitable, and fully integrated
pan-European pharmaceutical company with a portfolio of marketed
products, a direct sales and marketing organization in the major
European countries (UK, Germany, France, Italy and Spain), and a
pipeline of products in various stages of clinical
development.
Acura Pharmaceuticals, Inc., (formerly Halsey Pharmaceuticals) is a specialty pharmaceutical development company engaged in research, development and manufacture of innovative abuse deterrent, abuse resistant and tamper resistant formulations (the "Aversion® Technology") intended for use in orally administered opioid-containing prescription analgesic products.
AmeriFIT Nutrition Inc.
is a cutting edge, innovative leader in the nutritional supplement
industry, focused on building brands in the burgeoning women's health
and joint care categories.
Corium is a vertically integrated, revenue generating private company that is using its proprietary polymer (Corplex™) and mechanical microporation (MicroCor™) technologies to optimally deliver drugs across the skin and mucosa.
Dow Pharmaceutical Sciences specializes in development of topical drug products for pharmaceutical
and biotechnology clients.
EUSA Pharma, Inc., is a trans-Atlantic specialty pharmaceutical company focused on oncology and critical care. EUSA intends to build a portfolio of products that are on the market or in late-stage clinical trials through acquisitions and in-licensing. The company has a sales and marketing organization and commercial infrastructure in the US and all major European countries.
Healthcare Brands International (HBI), Ltd., is focused on acquiring, developing and investing in differentiated healthcare products to translate innovative science into meaningful consumer brands. HBI owns Antula, the leading independent OTC pharmaceutical company in the Nordic region.
Horizon Therapeutics, Inc., is a late stage biopharmaceutical company focused on rapid development of prescription drugs for mild to moderate pain relief. Horizon Therapeutics is creating novel therapies through innovative combinations of existing pharmaceutical products. The company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance.
MediciNova, Inc. is a pharmaceutical company that
creates value by in-licensing compounds from predominantly small to
mid-sized Japanese pharmaceutical companies
and advancing the clinical development of these in-licensed compounds by
conducting further trials throughout the world. MediciNova’s current
drug pipeline includes proprietary compounds that are in late-stage
clinical trials (Phase II or Phase III) in the following indications:
asthma,multiple sclerosis, cancer, anxiety disorders, and interstitial
cystitis. The company is listed on the Osaka (Hercules) Securities
Exchange, Code number: 4875.
Molecular Partners AG is a privately held biotech company focusing on the
commercialization of a novel class of biological drugs known as DARPins.
The company is using/exploiting this novel class of protein therapeutics
to create medicines for diseases with unmet medical need and to
dramatically improve existing therapies in ophthalmology, inflammation,
oncology and other disease areas. DARPins combine the high specificity,
selectivity and safety of monoclonal antibodies with many advantages of
small molecules, including high stability and low-cost production.
Palatin is an emerging leader in pharmaceutical research and development in the
areas of drug discovery, pre-clinical/clinical research and product
development.
Palmetto Pharmaceuticals (formerly eNOS Pharmaceuticals), LLC, has developed products that improve and restore blood flow and that reduce triglycerides through up-regulation of endothelial nitric oxide synthase (eNOS) enzyme. The company's first drug candidate, L-arginine Sustained Release for the management of hypertriglyceridaemia, is in clinical trials in Germany.
Prism Pharmaceuticals, Inc., which was incorporated in 2004 as a specialty pharmaceutical company, develops, acquires and markets pharmaceuticals for the treatment of cardiovascular conditions, including diabetes related disorders. The pharmaceutical products acquired and developed will be used to directly treat cardiovascular disease and diabetes, as well as their multi-system involvement.
Receptor BioLogix, Inc. is a biopharmaceutical company focused onthe development and commercialization of a newly discovered class of
protein therapeutics called Intron Fusion Proteins (IFP) to treat
cancer, autoimmune, metabolic and other diseases
Revance Therapeutics, Inc., (formerly Essentia Biosystems), is a specialty pharmaceutical company formed to discover, develop and commercialize therapeutic products for treating chronic disease and age-related changes to skin and soft tissue. The company’s core clinical targets are in areas of aesthetic medicine and therapeutic dermatology.
Salix Pharmaceuticals, Ltd. is a leading specialty pharmaceutical company providing solutions to
gastroenterologists and their patients.
Shire Pharmaceuticals Group is an international specialty pharmaceutical company with a strategic
focus on four therapeutic areas: central nervous system disorders,
metabolic diseases, oncology and gastroenterology.
Victory Pharma, Inc., a specialty pharmaceutical company, engages in acquiring, developing and marketing prescription pharmaceutical products for the treatment of pain and related conditions. The company also develops products that treat pain and minimize side effects associated with widely-used pain therapeutics. Its products include NAPRELAN tablets for the treatment of rheumatoid arthritis, osteoarthritis, XODO for the relief of moderate to moderately sever pain, and Dolgic Plus tablets for tension headache.
Xanodyne Pharmaceuticals, Inc., is a fully integrated, specialty pharmaceutical company that acquires, develops, and markets prescription pharmaceutical products in the women's health and pain management markets. Xanodyne Pharmaceuticals was formed from the merger of Xanodyne Pharmacal and Integrity Pharmaceuticals in February 2004.
ZIOPHARM Oncology, Inc., is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. |
